Haris Ali, MD
Hematology · Duarte, CANPI 1467672907
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $211,340 of the $310,074 with a category attached, or 68.2%. 16 manufacturers reported payments, led by Incyte Corporation at 47.5% of the total. Reporting peaked in 2024 at $66,101 and has fallen 58.1% since, to $27,725 in 2025. Among hematology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $959.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$147K
- GSK$45K
- Pharmaessentia USA Corporation$33K
- Bristol Myers Squibb$29K
- Sobi, Inc$26K
- Karyopharm Therapeutics Inc.$10K
- plus $21K from 10 others
Across 2,060 payments — averaging $3403.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$4.6M
- Karyopharm Therapeutics Inc.$2M
- Stemline Therapeutics Inc.$370K
- CTI Biopharma Corp.$34K
- National Marrow Donor Program$14K
- Novartis$1
What the payments were for
- Consulting fees$66,84022%
- Speaking & faculty fees$211,34068%
- Travel & lodging$24,8378%
- Food & beverage$6,8422%
- Education$2150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 158 | $147,283 |
| GSK | 36 | $44,802 |
| Pharmaessentia USA Corporation | 29 | $32,512 |
| Bristol Myers Squibb | 35 | $28,638 |
| Sobi, Inc | 12 | $25,938 |
| Karyopharm Therapeutics Inc. | 5 | $10,067 |
| Blueprint Medicines Corporation | 9 | $8,696 |
| Geron Corporation | 5 | $3,335 |
| Novartis | 7 | $2,726 |
| AbbVie | 8 | $2,345 |
| E.r. Squibb & Sons, L.L.C. | 2 | $2,134 |
| AstraZeneca(2 entities) | 13 | $1,358 |
| Inari Medical, Inc. | 1 | $189 |
| Sanofi | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$310,074 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 124 | $2,018,509 |
| OjjaaraMomelotinib Dihydrochloride | 46 | $1,279,300 |
| XospataGilteritinib Fumarate | 25 | $587,205 |
| ScemblixAsciminib Hydrochloride | 27 | $560,145 |
| PegasysPeginterferon Alfa-2a | 19 | $47,624 |
| Posaconazole | 21 | $24,523 |
| Atovaquone | 40 | $23,256 |
| EliquisApixaban | 14 | $9,196 |
| MyrbetriqMirabegron | 12 | $5,861 |
| Deferasirox | 11 | $3,359 |
| Potassium Chloride | 34 | $2,616 |
| Ursodiol | 34 | $2,572 |
| Tacrolimus | 26 | $2,230 |
| Hydroxyurea | 43 | $1,454 |
| Icosapent Ethyl | 12 | $926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $147,283 | $2,018,509124 claims |
| GSKOjjaara | $44,802 | $1,279,30046 claims |
| NovartisScemblix | $2,726 | $560,14527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 178 hematology providers in California.
Other hematology in Duarte
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Alexey DanilovDuarte$407K
- Tycel PhillipsDuarte$348K
- Amandeep SalhotraDuarte$214K
- Tanya SiddiqiDuarte$199K
- Scott GoldsmithDuarte$180K
- Ibrahim AldossDuarte$175K
- Alex HerreraDuarte$155K
- Geoffrey ShouseDuarte$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.